Click to cancel search
Login
Sign Up
Home Page
How It Works
Our Story
Symptom Checker
Second Opinion Finder
Newsroom
Partner With Us
MediFind Pro
FAQ
Are we missing a condition or feature you’d like to see? MediFind is always evolving and we’d love your feedback.
Submit Feedback
Advertising Policy
Privacy Policy
Terms & Conditions
Condition
Condition
Doctor
Symptom
Condition
Click to search for condition or expert
Login
Sign Up
Click to open main menu
Share
Share
Share
Click
Share
Share
Condition
Angioimmunoblastic T-cell Lymphoma
Symptoms, Doctors, Treatments, Research & More
Overview
Find a Doctor
Latest Research
Clinical Trials
Condition 101
What are the alternative names for Angioimmunoblastic T-cell Lymphoma?
Angioimmunoblastic with dysproteinemia lymphadenopathy
Top Global Doctors
Click to see doctor options
PG
Elite
Philippe Gaulard
Creteil, 11, FR
Click to see doctor options
KO
Elite
Koichi I. Ohshima
Kurume, 40, JP
Click to see doctor options
SH
Elite
Steven M. Horwitz
Oncology
Internal Medicine
New York, NY
Click to see doctor options
RA
Elite
Ranjana H. Advani
Oncology
Internal Medicine
Stanford, CA
Click to see doctor options
MY
Elite
Mamiko Yanagimoto-Sakata
Tsukuba, JP
Click to see doctor options
MK
Elite
Masaru Kojima
Kashiwa, 12, JP
Latest Research
Latest Advance
Study
Condition:
Peripheral T-cell Lymphoma
Journal:
International journal of hematology
Treatment Used:
Stem Cell Transplantation
Number of Patients:
374
Published —
April 17, 2020
The study researched the outcomes of stem cell transplantation for patients with peripheral T-cell lymphoma.
Clinical Trials
Clinical Trial
Drug
Status:
Not yet recruiting
Study Type:
Drug
Participants:
46
Start Date:
July 2020
A Phase 1a/1b Trial in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a Fenretinide Phospholipid Suspension (12.5 mg/mL) for Intravenous Infusion
Clinical Trial
Drug
Status:
Recruiting
Study Type:
Drug
Participants:
26
Start Date:
March 31, 2020
A Single-arm, Multiple Centers, Phase II Study Evaluating Rituximab in Combination With Chidamide and Lenalidomide for Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma (AITL)
